all

The NLA has released an official scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia. The statement provides insights and guidance for health care providers seeking to further their understanding of the benefits, risks and patient preferences of genetic testing. 

View the April 2020 Midwest quarterly e-newsletter by clicking here. 

Join us for our virtual business meeting!

On behalf of the National Lipid Association, the 2020 Annual Business Meeting will be held electronically Monday, June 8, 2020 from 6:00-6:30 PM ET.

Agenda: